Health
ATPCI: Trimetazidine Fizzles for Post-PCI Angina – Medscape
The antianginal was unable to provide added benefit when added to optimal medical therapy, but one expert questions: Was the right population studied?
Adding trimetazidine to optimal medical therapy does not improve outcomes following successful percutaneous coronary intervention (PCI) for stable angina or a nonST-elevated myocardial infarction (MI), results of the ATPCI trial show.
There was no benefit for the composite primary endpoint of cardiac death, hospitalization for cardiac events, or recurrent/persistent angina requiring an addition, switch, or increased dose of antianginal therapies, or requiring coronary angiography (hazard ratio…
-
General22 hours agoHow the Maroons salvaged Origin pride, as Southwell proves she’s the next great halfback
-
General21 hours agoIsrael announces major expansion of West Bank settlements despite sanctions threat
-
General19 hours agoJudge issues injunction over Trump plan to limit Harvard enrolments
-
Noosa News6 hours agoPacific Airshow Gold Coast 2025 cancelled amid beach safety concerns